New Pneumococcal Vaccines for Prevention of Invasive Pneumococcal Disease in Adult Patients With Inflammatory Bowel Disease.
Sheena Crosby, Michael J Schuh, Michelle Becker, Marina Ivanov, Freddy Caldera, Francis A Farraye
Author Information
Sheena Crosby: Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA. ORCID
Michael J Schuh: Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA.
Michelle Becker: Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Marina Ivanov: Department of Pharmacy, Mayo Clinic, Scottsdale, AZ, USA.
Freddy Caldera: Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, USA. ORCID
Francis A Farraye: Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA. ORCID
Patients with inflammatory bowel disease (IBD) are at a high risk of developing invasive pneumococcal infection both before and after they are diagnosed. The Advisory Committee on Immunization Practices now endorses use of 2 new pneumococcal conjugate vaccines, PCV15 (Vaxneuvance) and PCV20 (Prevnar 20), for patients who have never received a pneumococcal conjugate vaccine or those with unknown vaccination history. Previous studies have shown that pneumococcal vaccination can decrease the risk of developing severe pneumococcal disease; therefore, it is important that patients with IBD receive pneumococcal vaccination. This report aims to inform clinicians who care for patients with IBD about the changes in immunization practices, as it pertains to pneumococcal vaccination and provides appropriate direction on administering vaccination series.
